Pivitko 200mg

Pivitko 200mg is a prescription medication used to treat advanced or metastatic breast cancer in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) disease. It is a PI3K inhibitor that works by blocking the activity of the PI3K/AKT pathway, which is a key signaling pathway that promotes cancer cell growth and survival.

Composition:

• Pivitko 200mg: Alpelisib (200mg) Tablet

Mechanism of Action:

Alpelisib, the active ingredient in Pivitko, works by:

1. Inhibiting the activity of phosphatidylinositol 3-kinase (PI3K), an enzyme that is involved in the PI3K/AKT pathway.
2. Blocking the activation of AKT, a protein that promotes cell growth and survival.
3. Reducing the expression of proteins that promote cell growth and survival.

Indications:

Pivitko is approved for the treatment of:

1. Advanced or metastatic breast cancer in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) disease.
2. Patients who have received prior endocrine therapy and chemotherapy.

Dosage:

The recommended dosage of Pivitko is:

• 200mg orally, once daily, in combination with fulvestrant or an aromatase inhibitor.
• The recommended duration of treatment is until disease progression or unacceptable toxicity.

Side Effects:

Common side effects of Pivitko include:

1. Fatigue
2. Diarrhea
3. Rash
4. Nausea
5. Vomiting
6. Abdominal pain
7. Decreased appetite
8. Increased risk of infections
9. Increased risk of gastrointestinal perforation
10. Increased risk of hypocalcemia

Recommendation:

Pivitko is recommended for patients with advanced or metastatic breast cancer who have received prior endocrine therapy and chemotherapy.

Important Note:

• Patients taking Pivitko should be closely monitored for signs of liver damage, kidney damage, or changes in blood pressure.
• Patients taking Pivitko should avoid taking medications that may interact with it, such as anticoagulants or medications that can increase the risk of bleeding.
• Pregnant or breastfeeding women should not use Pivitko, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Pivitko and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of liver disease or kidney disease should be closely monitored while taking Pivitko.
• Patients taking Pivitko should avoid taking medications that may increase the risk of liver damage or kidney damage.
• Patients with a history of gastrointestinal disorders should be closely monitored while taking Pivitko.

Contraindications:

• Patients with severe liver disease or severe kidney disease should not use Pivitko.
• Patients who are pregnant or breastfeeding should not use Pivitko.
• Patients who are allergic to alpelisib or any other component of Pivitko should not use it.